NASDAQ: CODX - Co-Diagnostics, Inc.

Yield per half year: -72.12%
Dividend yield: 0%
Sector: Healthcare

Share chart Co-Diagnostics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Co-Diagnostics, Inc.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

more details
It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2017-07-12
ISIN US1897631057
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.codiagnostics.com
Цена ао 0.3623
Change price per day: -1.34% (0.3052)
Change price per week: -11.42% (0.3399)
Change price per month: -10.65% (0.337)
Change price per 3 month: -56.34% (0.6897)
Change price per half year: -72.12% (1.08)
Change price per year: -72.38% (1.09)
Change price per 3 year: -93.38% (4.55)
Change price per 5 year: -97.75% (13.41)
Change price per year to date: -58.75% (0.73)
All parameters

Underestimation

Title Value Grade
P/S 5.42 2
P/BV 0.3909 10
P/E 0 0
EV/EBITDA -0.5283 0
Total: 5.25

Efficiency

Title Value Grade
ROA, % -47.25 0
ROE, % -53.65 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0556 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -94.75 0
Yield Ebitda, % -190.64 0
Yield EPS, % -181.63 0
Total: 0
More

Institutions Volume Share, %
Vanguard Group Inc 1781283 5.7
Renaissance Technologies, LLC 617000 1.97
Blackrock Inc. 501830 1.61
Geode Capital Management, LLC 294422 0.94
Bridgeway Capital Management, Inc. 272900 0.87
Bank Of New York Mellon Corporation 145621 0.47
Kestra Advisory Services, LLC 138607 0.44
Susquehanna International Group, LLP 107699 0.34
State Street Corporation 100647 0.32
Citadel Advisors Llc 96647 0.31



Head Job title Payment Year of birth
Mr. Dwight H. Egan Chairman & CEO 415.75k 1953 (72 years)
Mr. Brian L. Brown CPA CFO & Company Secretary 338.92k 1976 (49 years)
Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board 237.5k 1977 (48 years)
Mr. Dan Bohrer CPA Vice President of Finance & Accounting N/A
Mr. Andrew Benson Head of Investor Relations N/A
Dr. Mayuranki Almaula Senior Vice President of Overseas Operations & Strategic Alliances N/A
Mr. Richard David Abbott President N/A 1972 (53 years)
Mr. David Nielsen Chief Operating Officer N/A
Mr. Christopher Thurston Chief Technology Officer N/A
Mr. Cameron Gundry Head of Commercialization LATAM/EUR

Address: United States, Salt Lake City. UT, 2401 South Foothill Drive - open in Google maps, open in Yandex maps
Website: https://www.codiagnostics.com